Amylyx Pharmaceuticals, Inc.(AMLX)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Amylyx Pharmaceuticals, Inc. (AMLX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMLX at 8.7/100 on a 32-signal composite quality model, placing it at rank #2,731 of 2,753 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (1.3) and revenue growth (1.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 4.9/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of AMLX by reported 13-F value include FMR, BlackRock, PERCEPTIVE ADVISORS, based on the most recent SEC filings. AMLX trades on the Nasdaq exchange and files with the SEC under CIK 1658551. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Amylyx Pharmaceuticals, Inc. directly from SEC EDGAR.